GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abera Bioscience AB (XSAT:ABERA) » Definitions » Debt-to-Revenue

Abera Bioscience AB (XSAT:ABERA) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abera Bioscience AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Abera Bioscience AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Abera Bioscience AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Abera Bioscience AB's annualized Revenue for the quarter that ended in Mar. 2024 was kr0.00 Mil.


Abera Bioscience AB Debt-to-Revenue Historical Data

The historical data trend for Abera Bioscience AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abera Bioscience AB Debt-to-Revenue Chart

Abera Bioscience AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Abera Bioscience AB Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Abera Bioscience AB's Debt-to-Revenue

For the Biotechnology subindustry, Abera Bioscience AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abera Bioscience AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abera Bioscience AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Abera Bioscience AB's Debt-to-Revenue falls into.



Abera Bioscience AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Abera Bioscience AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Abera Bioscience AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Abera Bioscience AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Abera Bioscience AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Abera Bioscience AB (XSAT:ABERA) Business Description

Traded in Other Exchanges
N/A
Address
Svetsarvagen 15, Solna, SWE, SE-17141
Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.

Abera Bioscience AB (XSAT:ABERA) Headlines

No Headlines